Additional file 1 of Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance

Additional file 1: Figure S1. CYLD-knockdown by CYLD-specific siRNA at mRNA level. Figure S2. The proteins involved in Akt and ERK signaling pathway in CYLD-negative OSCC cells. Figure S3. Cell survival rate in CYLD-knockdown OSCC cells by different siCYLD #2 and in other OSCC cells. Figure S4. Gefitinib treatment increased the expression of E-cadherin, an EMT biomarker. Figure S5. NF-κB signaling pathway does not participate in cell survival in CYLD-negative OSCC cells. Figure S6. TGF-β signaling pathway does not participate in cell survival in CYLD-negative OSCC cells. Figure S7. Cetuximab treatment suppressed anchorage-independent growth of CYLD-negative OSCC cells. Figure S8. Immunohistochemical analysis for OSCC marker expression in tumor tissues from PDX models (PDX st.1 & PDX st.2)